SCHEMBL21691093

SCHEMBL21691093

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1noc2ccc(CN3C(=O)c4ccccc4C3O)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.48
LMNA P02545 3/20 0.39
ALDH1A1 P00352 4/20 0.39
PKM P14618 1/20 0.39
GAA P10253 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
HSD17B10 Q99714 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HKDC1 Q2TB90 1/20 0.34
MAPT P10636 3/20 0.34
MAPK1 P28482 2/20 0.34
GLA P06280 1/20 0.34
PDCD1 Q15116 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3743537 0.85 KMT2A (0.40) HPGDLMNAPKMKDM4EMAPT
SCHEMBL23279822 0.81 KMT2A (0.35) HPGDLMNAPKML3MBTL1KDM4E
SCHEMBL16880854 0.80 KMT2A (0.40) HPGDPKMMAPTPDCD1CD274
SCHEMBL1759492 0.75 PDPK1 (0.35) ALDH1A1MAPTKMT2A
SCHEMBL12636119 0.71 HIF1A (0.38) GAAKDM4EMAPTMEN1KMT2A
SCHEMBL16880936 0.70 AKT1 (0.35) LMNAMAPTPDCD1CD274
SCHEMBL1759441 0.70 MAPT (0.46) LMNAMAPTPOLB
SCHEMBL14933657 0.70 ESR1 (0.42) HPGDALDH1A1MAPTCYP1A2CYP2D6
SCHEMBL8265372 0.69 SOS1 (0.39) ALDH1A1HSD17B10KDM4EMAPTTSHR
SCHEMBL23279865 0.68 KMT2A (0.34) LMNAMAPTMAPK1POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11021463-B2 Therapeutic inhibitory compounds ATTUNE PHARMACEUTICALS, INC. (US) 2021-06-01 US disclosed
US-20200031800-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200031800-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 HPGD 140/4885LMNA 2032/4885ALDH1A1 1717/4885
US-11021463-B2 Therapeutic inhibitory compounds KLKB1, SERPINB1, SERPINE1 HPGD 140/4885LMNA 2032/4885ALDH1A1 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.